Insider Monkey

It’s a well-established truth that insiders often benefit from their own trades. In 2009, over 59,000 insiders reported their transactions to the SEC, while the previous year saw more than 65,000 filings. Simply copying all these insiders isn’t likely to be effective. However, focusing on the top-performing insiders with proven success can be much more rewarding. Insider Monkey employs a mixed assessment approach that analyzes insider trades and other market irregularities to filter out the most promising insiders to follow. Additionally, Insider Monkey offers well-researched, evidence-based articles to help individual investors understand the complexities of investing.

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#22597

United States

#7501

Finance/Investing

#80

Traffic sources

Monthly visitors

Articles

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress

5 days ago | insidermonkey.com | Fatima Gulzar

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It presented encouraging three-year follow-up data from their Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the EAACI Congress 2025. All 10 patients were free of attacks and treatment for a median of 23 months after receiving a single dose of lonvo-z, which led to a 98% mean reduction in monthly HAE attacks.
Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions

5 days ago | insidermonkey.com | Fatima Gulzar

Twist Bioscience Corporation (NASDAQ:TWST) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. The firm has expanded its relationship with Element Biosciences to produce end-to-end Next Generation Sequencing (NGS) solutions. Twist Bioscience Corporation (NASDAQ:TWST)’s library prep and target enrichment workflows are now integrated with Element’s AVITI™ devices and Trinity™ flowcells.
Lilly To Acquire Verve For One-Time Cardiovascular Treatments

5 days ago | insidermonkey.com | Fatima Gulzar

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 billion. Depending on future milestones, Lilly will pay $10.50 per share in cash, or roughly $1.0 billion, plus a contingent value right of up to $3.00 per share. The purchase is anticipated to be completed in Q3 2025 and represents a 113% premium over Verve Therapeutics, Inc.
Exact Sciences Expands Oncodetect Validation, Unveils MRD Innovation Roadmap.

5 days ago | insidermonkey.com | Fatima Gulzar

Exact Sciences Corporation (NASDAQ:EXAS) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has released fresh data from the Beta-CORRECT study that validates the clinical efficacy of its tumor-informed Oncodetect™ test for recurrence monitoring in stage II-IV colorectal cancer. The findings, presented at ASCO 2025, revealed that patients with ctDNA-positive results after therapy and during surveillance had a 24- and 37-fold greater risk of recurrence, respectively.
10x Genomics Settles Patent Dispute With Bruker

5 days ago | insidermonkey.com | Fatima Gulzar

10x Genomics, Inc. (NASDAQ:TXG) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has announced a global settlement agreement with Bruker Corporation, which resolves all outstanding patent litigation between the two firms. As per the agreement, from Q3 2025 to Q2 2026, Bruker will pay 10x Genomics, Inc. (NASDAQ:TXG) $68 million in equal quarterly installments.
First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome

5 days ago | insidermonkey.com | Fatima Gulzar

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. The initial participant in the pivotal Phase 3 REVEAL trial, which is assessing ION582 for Angelman syndrome, a severe neurodevelopmental disease, has been dosed by Ionis Pharmaceuticals, Inc. (NASDAQ:IONS). The randomized, placebo-controlled research will include approximately 200 people with UBE3A gene deletions or mutations.
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint

5 days ago | insidermonkey.com | Fatima Gulzar

uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V. (NASDAQ:QURE) regulatory update on AMT-130, an experimental gene therapy for Huntington’s disease. uniQure N.V. (NASDAQ:QURE) declared that it has partnered with the FDA to seek an expedited approval process for AMT-130.
Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating

5 days ago | insidermonkey.com | Fatima Gulzar

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of Barclays kept BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) at a Buy rating with a price target of $86.00 in a report published on June 10. According to BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s most recent earnings report, the firm made $745.15 million in revenue and $185.69 million in net profit for the quarter that ended on March 31.
Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia.

5 days ago | insidermonkey.com | Fatima Gulzar

Biogen Inc. (NASDAQ:BIIB) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has begun dosing in the global Phase 3 BRAVE trial to test omaveloxolone (SKYCLARYS®) in children aged 2 to 16 with Friedreich ataxia (FA), a rare neurological illness. About 255 participants will be included in the randomized, double-blind experiment, which will have a 52-week treatment duration and an open-label extension.
Canaccord Raises Price Target Of Illumina, Inc. (ILMN).

5 days ago | insidermonkey.com | Fatima Gulzar

Illumina, Inc. (NASDAQ:ILMN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Kyle Mikson, an analyst at Canaccord Genuity, increased his price objective for Illumina, Inc. (NASDAQ:ILMN) shares from $87 to $99 on June 11 while keeping his rating at Hold. The announcement comes after Illumina, Inc. (NASDAQ:ILMN) CEO Jacob Thaysen stated in a podcast that when pricing pressures lessen, revenue improvements may be driven by robust volume growth from clinical customers.